Synonym |
Thai / English name |
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : (-)epigallocatechin-3-gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 10-40 micromolar/LDuration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : NS-398Dose/Conc.(drug) : 10 micromolar/LResult : PositiveRemark : Type of experiment: human prostate cancer cells LNCaP, PC-3, and CWR22Rn1 Results: Combination of EGCG and NS-398 resulted in enhanced (a) cell growth inhibition; (b) apoptosis induction; (c) expression of Bax, pro-caspase-6, and pro-caspase-9, and poly (ADP) ribose polymerase cleavage; (d) inhibition of peroxisome proliferator activated receptor g; and (e) inhibition of nuclear factor-kB compared with the additive effects of the two agents alone, suggesting a possible synergism.Note : Data incomplete
Part Used : -Activity : CELL GROWTH INHIBITION EFFECTSolvent/Active Compound : (-)epigallocatechin-3-gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 10-40 micromolar/LDuration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : NS-398Dose/Conc.(drug) : 10 micromolar/LResult : PositiveRemark : Type of experiment: human prostate cancer cells LNCaP, PC-3, and CWR22Rn1 Results: Combination of EGCG and NS-398 resulted in enhanced (a) cell growth inhibition; (b) apoptosis induction; (c) expression of Bax, pro-caspase-6, and pro-caspase-9, and poly (ADP) ribose polymerase cleavage; (d) inhibition of peroxisome proliferator activated receptor g; and (e) inhibition of nuclear factor-kB compared with the additive effects of the two agents alone, suggesting a possible synergism.Note : Data incomplete
Part Used : -Activity : APOPTOSIS INDUCTIONSolvent/Active Compound : (-)epigallocatechin-3-gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 10-40 micromolar/LDuration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : NS-398Dose/Conc.(drug) : 10 micromolar/LResult : PositiveRemark : Type of experiment: human prostate cancer cells LNCaP, PC-3, and CWR22Rn1 Results: Combination of EGCG and NS-398 resulted in enhanced (a) cell growth inhibition; (b) apoptosis induction; (c) expression of Bax, pro-caspase-6, and pro-caspase-9, and poly (ADP) ribose polymerase cleavage; (d) inhibition of peroxisome proliferator activated receptor g; and (e) inhibition of nuclear factor-kB compared with the additive effects of the two agents alone, suggesting a possible synergism.Note : Data incomplete
Part Used : -Activity : POLY(ADP-RIBOSE) POLYMERASE INHIBITIONSolvent/Active Compound : (-)epigallocatechin-3-gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 10-40 micromolar/LDuration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : NS-398Dose/Conc.(drug) : 10 micromolar/LResult : PositiveRemark : Type of experiment: human prostate cancer cells LNCaP, PC-3, and CWR22Rn1 Results: Combination of EGCG and NS-398 resulted in enhanced (a) cell growth inhibition; (b) apoptosis induction; (c) expression of Bax, pro-caspase-6, and pro-caspase-9, and poly (ADP) ribose polymerase cleavage; (d) inhibition of peroxisome proliferator activated receptor g; and (e) inhibition of nuclear factor-kB compared with the additive effects of the two agents alone, suggesting a possible synergism.Note : Data incomplete
Part Used : -Activity : PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) INHIBITIONSolvent/Active Compound : (-)epigallocatechin-3-gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 10-40 micromolar/LDuration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : NS-398Dose/Conc.(drug) : 10 micromolar/LResult : PositiveRemark : Type of experiment: human prostate cancer cells LNCaP, PC-3, and CWR22Rn1 Results: Combination of EGCG and NS-398 resulted in enhanced (a) cell growth inhibition; (b) apoptosis induction; (c) expression of Bax, pro-caspase-6, and pro-caspase-9, and poly (ADP) ribose polymerase cleavage; (d) inhibition of peroxisome proliferator activated receptor g; and (e) inhibition of nuclear factor-kB compared with the additive effects of the two agents alone, suggesting a possible synergism.Note : Data incomplete
Part Used : -Activity : NUCLEAR FACTOR KAPPA-BETA INHIBITIONSolvent/Active Compound : (-)epigallocatechin-3-gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 10-40 micromolar/LDuration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : NS-398Dose/Conc.(drug) : 10 micromolar/LResult : PositiveRemark : Type of experiment: human prostate cancer cells LNCaP, PC-3, and CWR22Rn1 Results: Combination of EGCG and NS-398 resulted in enhanced (a) cell growth inhibition; (b) apoptosis induction; (c) expression of Bax, pro-caspase-6, and pro-caspase-9, and poly (ADP) ribose polymerase cleavage; (d) inhibition of peroxisome proliferator activated receptor g; and (e) inhibition of nuclear factor-kB compared with the additive effects of the two agents alone, suggesting a possible synergism.Note : Data incomplete